T
Thrombolex
Creating a continuous stream of new products based on the original BASHIR platform technology, which will improve the treatment outcomes for patients suffering from acute VTE conditions
About Thrombolex
Founded in 2016, Thrombolex, Inc. specializes in the design, development, manufacture, and distribution of advanced endovascular catheters. These catheters are primarily used in interventional procedures, specifically for catheter-directed thrombolysis to treat large thrombus in patients suffering from acute venous thromboembolism (VTE). The company's innovative approach aims to reduce the amount of thrombolytics needed and shorten treatment times, which benefits patients and lowers healthcare costs. Thrombolex serves medical professionals and healthcare providers who treat conditions like deep vein thrombosis and pulmonary embolism. Operating in the medical technology market, Thrombolex generates revenue through the sale of its proprietary catheters and related medical devices. The business model focuses on leveraging cutting-edge technology to improve patient outcomes and streamline interventional procedures.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- New Britain, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 72.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Cardiology and cardiovascular, Catheters, Spinout, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2026 | $50M | $200M | OrbiMed | ↗ |
| EARLY VCOther financing | Jun 2024 | $4.8M | $19M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Thrombolex is 1.5K monthly website visits, down 21.1% over the last three months. Thrombolex's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors2 additional known investors
Temple University
Temple University Hospital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Thrombolex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Thrombolex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.